Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring
ConditionDiabetes Mellitus
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAbbott Diabetes Care
About this trial
This study is to see if the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) will help prolong the length of time people with diabetes maintain adherence to glucagon-like peptide 1 (GLP-1/GIP) agonists.
Eligibility criteria
Qualifiers
Subject must be at least 18 years of age.
Subject must be able to read and understand English.
Subject must have a type 2 diabetes diagnosis.
In the investigator's opinion, subject must meet the criteria for beginning use of GLP-1 or GIP/GLP-1 medications for management of their diabetes.
Disqualifiers
Subject is a member of the Study Staff.
Subject has a diagnosis of type 1 or gestational diabetes.
Subject is currently using or has previously used GLP-1 or GIP/GLP-1 drugs for any reason.
Subject is currently using a Continuous Glucose Monitor (CGM) as their standard of care device to manage their diabetes.
Trial design
Treatments tested in this trial
- To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists
Treatment groups
800 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov